Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06459988 in advanced EGFRm NSCLC
NCT02297425Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pf-06459988 in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities at 21 days and Objective Response Rate up to 24 months. Planned start Jan 2015; status: withdrawn.
02
Drugs
pf-06459988
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02297425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297425.